Dactinomycin
- Generic Name
- Dactinomycin
- Brand Names
- Cosmegen
- Drug Type
- Small Molecule
- Chemical Formula
- C62H86N12O16
- CAS Number
- 50-76-0
- Unique Ingredient Identifier
- 1CC1JFE158
- Background
A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (Fro...
- Indication
For the treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen
- Associated Conditions
- Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Osteosarcoma, Ovarian Cancer, Rhabdomyosarcomas, Wilms' tumor, Metastatic nonseminomatous Testicular cancer
- Associated Therapies
- -
Evolutionary Therapy for Rhabdomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2020-05-14
- Last Posted Date
- 2024-11-28
- Target Recruit Count
- 28
- Registration Number
- NCT04388839
- Locations
- 🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Primary Children's Medical Center/Utah, Salt Lake City, Utah, United States
Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor
- First Posted Date
- 2015-12-24
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Weiguo Lv
- Target Recruit Count
- 214
- Registration Number
- NCT02639650
- Locations
- 🇨🇳
Weiguo Lv, Hangzhou, Zhejiang, China
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2015-10-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 325
- Registration Number
- NCT02567435
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Atrium Health Navicent, Macon, Georgia, United States
🇺🇸Springfield Memorial Hospital, Springfield, Illinois, United States
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
- Conditions
- Interventions
- Drug: VincristineDrug: DactinomycinDrug: CyclophosphamideProcedure: Surgical ResectionProcedure: RadiationDrug: Myeloid Growth FactorDrug: BevacizumabProcedure: Lymph Node SamplingDrug: SorafenibDrug: ^1^1C-methionineDrug: IrinotecanDrug: IfosfamideDrug: EtoposideDrug: Etoposide PhosphateDrug: DoxorubicinDrug: Dexrazoxane
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 98
- Registration Number
- NCT01871766
- Locations
- 🇺🇸
Nemours Children's Clinic, Jacksonville, Florida, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸University of Florida Proton Therapy Institute, Jacksonville, Florida, United States
International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry
- Conditions
- Interventions
- First Posted Date
- 2011-11-03
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Children's Hospitals and Clinics of Minnesota
- Target Recruit Count
- 156
- Registration Number
- NCT01464606
- Locations
- 🇺🇸
Anne K Harris, Minneapolis, Minnesota, United States
Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
- First Posted Date
- 2009-11-17
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Tufts Medical Center
- Target Recruit Count
- 27
- Registration Number
- NCT01014767
- Locations
- 🇳🇿
Christchurch Hospital, Christchurch, New Zealand
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
🇭🇺Semmelweis University, Budapest, Hungary
A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer
- Conditions
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2007-06-26
- Target Recruit Count
- 24
- Registration Number
- NCT00491946
- Locations
- 🇺🇸
Abramson Research Center, Philadelphia, Pennsylvania, United States
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
- Conditions
- Interventions
- Biological: filgrastimDrug: cisplatinDrug: cyclophosphamideDrug: cytarabineDrug: dexrazoxane hydrochlorideDrug: doxorubicin hydrochlorideDrug: etoposideDrug: leucovorin calciumDrug: methotrexateDrug: temozolomideDrug: therapeutic hydrocortisoneDrug: vincristine sulfateRadiation: radiation therapyDrug: Dactinomycin
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT00084838
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus, Atlanta, Georgia, United States
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2004-01-12
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 390
- Registration Number
- NCT00075582
- Locations
- 🇺🇸
Driscoll Children's Hospital, Corpus Christi, Texas, United States
🇺🇸West Virginia University Charleston, Charleston, West Virginia, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.